|
99751 |
Synergistic Engineering of Side Chains and Backbone Regioregularity of Polymer Acceptors for High‐Performance All‐Polymer Solar Cells with 15.1% Efficiency (Adv. Energy Mater. 3/2022)
Enthalten in Advanced energy materials Bd. 12, 2022, Nr. 3. 1 S.
|
|
|
|
99752 |
Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004–2019
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 277-280. 4 S.
|
|
|
|
99753 |
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 262-276. 15 S.
|
|
|
|
99754 |
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 262-276. 15 S.
|
|
|
|
99755 |
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 251-261. 11 S.
|
|
|
|
99756 |
Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
Enthalten in Case reports in nephrology and dialysis Bd. 12, 2022, Nr. 3: 238-247. 10 S.
|
|
|
|
99757 |
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 238-250. 13 S.
|
|
|
|
99758 |
Keratoprothesen: letzte Hoffnung bei schwersten Hornhauterkrankungen
Enthalten in Augenheilkunde up2date Bd. 12, 2022, Nr. 03: 229-245
|
|
|
|
99759 |
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 229-237. 9 S.
|
|
|
|
99760 |
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
Enthalten in Liver cancer Bd. 12, 2022, Nr. 3: 209-217. 9 S.
|
|
Administration
